ARTICLE | Clinical News
Atrix reports Phase III data for 3-month Leuprogel
July 10, 2001 7:00 AM UTC
ATRX said that its 3-month Leuprogel leuprolide depot to treat prostate cancer suppressed testosterone levels to <50 ng/dl in all 117 patients in a Phase III study. Based on the data, the company expe...